Pitavastatin
Top View
- Pitavastatin: an Overview of the LIVES Study
- Cardiovascular Drugs: Statins and Lipid Lowering Agents
- Cholesterol-Lowering Agents
- Australian Public Assessment Report for Pitavastatin
- For Review at September 24, 2020, Meeting: Antihyperlipidemics
- Statin-Related Myotoxicity: a Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components
- Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation
- Fenofibrate Toxicity and Impact on Clinical Biomarkers in Patients with Dyslipidaemia
- Hyperlipidemia
- Combination Therapy with Pemafibrate (K-877)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Therapeutic Class Overview Bile Acid Sequestrants
- Study Protocol 1002-048 Amendment 2, 10 February 2017
- Report on the Deliberation Results June 13, 2017 Pharmaceutical
- Nikita® (Pitavastatin) – New Drug Approval
- After 52 Weeks, Pitavastatin Is Superior to Pravastatin for LDL-C Lowering in Patients with HIV
- LIVALO (Pitavastatin)
- LIVALO (Pitavastatin) Fact Sheet for Media